

ATTY. ~~RE~~CKET NO.  
247/164SERIAL NO.  
09/433,418

APPLICANT:

Joel B. Epstein

FILING DATE:

November 4, 1999

GROUP:

1614

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S  
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

<i>MB</i>	BU	Halliday, GM, Knight, BA, Muller, HK. Reduction In Murine Langerhans Cell ATPase Staining Following Topical But Not Systemic Treatment with Steroid and Non-Steroid Immunosuppressants. Br J Dermatol 1986; 114:83-89.
<i>MB</i>	BV	Mornington, B. The Place of Azathioprine in the Treatment of Auto-Immune Diseases. Leb Med J 1973; 26(1): 21-30.



EXAMINER:

DATE CONSIDERED:

03/06/01

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609;  
Draw line through citation if not in conformance and not considered. Include a copy of this form with next  
communication to applicant

ATTY. ~~CKET~~ NO.  
247/164SERIAL NO.  
09/433,418LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S  
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT:  
Joel B. EpsteinFILING DATE:  
November 4, 1999GROUP:  
1614 1617

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
MB	AA	3,056,785	2/26/62	Hitchings et al.	260	252	3/21/60
	AB	4,996,193	2/26/91	Hewitt et al.	514	11	3/3/89
	AC	5,204,329	4/20/93	Ackerman et al.	514	15	6/11/90
	AD	5,310,545	5/10/94	Eisen	424	49	1/15/93
	AE	5,540,931	7/30/96	Hewitt et al.	424	434	6/24/94
	AF	5,637,616	6/10/97	Sharpe et al.	514	562	10/5/93
	AG	5,639,759	6/17/97	Magolda et al.	514	285	3/27/95
	AH	5,716,648	2/10/98	Halokov et al.	424	682	12/21/95
	AI	5,691,343	11/25/97	Sandborn	514	262	3/30/95
↓	AJ	5,733,915	3/31/98	Sandborn et al.	514	262	3/30/95
MB	AK	5,905,081	5/18/99	Sandborn	514	262	8/1/97


## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB	TRANSLATION YES NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

MB	AL	Woo, SB, Lee, SJ, Schubert, MM. Graft-vs.-host disease. Crit Rev Oral Biol Med 1997; 8(2):201-216.
↓	AM	Schubert, MM, Sullivan, KM. Recognition, incidence, and management of oral graft-versus-host disease. NCI Monogr 1990; (9):135-143.
MB	AN	Nakamura, S, Hiroki, A, Shinohara, M, et al. Oral involvement in chronic graft-versus-host disease after allogeneic bone marrow transplantation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996; 82(5):556-563.

EXAMINER:

  
 Not Yet Assigned

DATE CONSIDERED:

03/16/01

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609;  
 Draw line through citation if not in conformance and not considered. Include a copy of this form with next  
 communication to applicant

## LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY.  TICKET NO.  
247/164SERIAL NO.  
09/433,418APPLICANT:  
Joel B. EpsteinFILING DATE:  
November 4, 1999GROUP:  
1614

<i>MS</i>	AO	Epstein JB, Reece, DE. Topical cyclosporin A for treatment of oral chronic graft-versus-host disease. Bone Marrow Transplant 1994; 13:81-86.
	AP	Epstein JB, Truelove, EL. Topical cyclosporin in a bioadhesive for treatment of oral lichenoid mucosal reaction. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996; 82:532-536.
	AQ	Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporin, and methotrexate. Am J Gastroenterol 1996; 91(3):423-433.
	AR	Winklestein A. The effects of azathioprine and 6-MP on immunity. J Immunopharmacol 1979; 1:429-454.
	AS	Brogan M, Hiserodt J, Oliver M, et al. The effect of 6-mercaptopurine on natural killer-cell activities in Crohn's disease. J Clin Immunol 1985; 5:204-11.
	AT	Brogan M, Stevens R, Hiserodt J, et al. Effects of 6-MP on the impaired in vivo humoral responsiveness in Crohn's disease. Gastroenterol 1984; 86:A1035.
	AU	Lozada F. Prednisone and azathioprine in the treatment of patients with vesiculocerosive oral diseases. Oral Surg Oral Med Oral Pathol 1981; 52(3):257-260.
	AV	Robinson JR, Lozada-Nur F, Frieden I. Oral pemphigus vulgaris. A review of the literature and a report on the management of 12 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997; 84:349-355.
	AW	Lear, JT, English, JSC. Erosive and generalized lichen planus responsive to azathioprine. Clin Exper Derm 1996; 21:56-57.
	AX	Allen LV Jr, Erickson MA. Stability of acetazolamide, allopurinol, azathioprine, clonazepam, and flucytosine in extemporaneously compounded oral liquids. Am J Health-Syst Pharm 1996; 53:1944-1949.
	AY	Eggleston DJ, Nally FF. Treatment of aphthous ulceration with topical azathioprine. A double blind trial. Br J Oral Surg 1972; 9(3):233-236.
	AZ	Suchko VI, Mashchenko IS. Local use of an azathioprine suspension in a dimexide solution in the combined treatment of parodontosis. Stomologica (Mosk) 1981; 60(3): 28-30.
	BA	Elliot JH, Leibowitz HM. Chemotherapeutic immunosuppression of the corneal graft reaction. 3. Topical azathioprine. Arch Ophthalmol 1966; 76(5):709-711.
	BB	Mackay IR, Bignell JL, Smith PH, Crawford BA. Prevention of corneal-graft failure with the immunosuppressive drug azathioprine. Lancet 1967; 514 (2):479-482.
<i>MS</i>	BC	Choi PM, Targan SR. Immunomodulator therapy in inflammatory bowel disease. Dig Dis Sci 1994; 39(9):1885-1892.
<i>MS</i>	BD	Stotland BR, Lichtenstein GR. Newer treatments for inflammatory bowel disease. Prim Care 1996; 3(3):577-608.

EXAMINER:

*Not Yet Assigned*

DATE CONSIDERED:

03/16/01

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S  
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. ~~████████~~CKET NO.  
247/164SERIAL NO.  
09/433,418APPLICANT:  
Joel B. EpsteinFILING DATE:  
November 4, 1999GROUP:  
1614

FEB 17 2000

PATENT &amp; TRADEMARK OFFICE

<i>WB</i>	BE	Zins BJ, Sandborn WJ, McKinney JA, et al. A dose-ranging study of azathioprine pharmacokinetics after single-dose administration of a delayed-release oral formulation. <i>J Clin Pharmacol</i> 1997; 37:38-46.
	BF	Van Os EC, Zins WJ, Sandborn WJ, et al. Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. <i>Gut</i> 1996; 39:63-68.
	BG	Epstein JB, Priddy RW, Sherlock CH. Hairy leukoplakia-like lesions in immunosuppressed patients following bone marrow transplantation. <i>Transplantation</i> 1988; 46:462-4.
	BH	Epstein JB, Sherlock CH, Wolber RA. Hairy leukoplakia after bone marrow transplantation. <i>Oral Surg Oral Med Oral Pathol</i> 1993; 75:690-5.
	BI	Scully, C, Paes de Llmeida, O, Porter, SR, Gilkes, JJH. Pemphigus vulgaris: the manifestations and long-term management of 55 patients with oral lesions. <i>Br J Dermatol</i> 1999; 140:84-89.
	BJ	Lever, WF. Pemphigus and pemphigoid. A review of the advances made since 1964. <i>J Amer Acad Dermatol</i> . 1979; 1(1):2-31.
	BK	Anstey, A, Lear, JT. Azathioprine: clinical pharmacology and current indications in autoimmune disorders. <i>BioDrugs</i> 1998; 9(1):33-47.
	BL	Glied, M, Rico, JM. Treatment of autoimmune blistering diseases. <i>Dermatol Clin</i> 1999; 17(2):431-330.
	BM	Eisen, D, Ellis, CN, et al. Effect of Topical Cyclosporine Rinse on Oral Lichen Planus. <i>New Engl J Med</i> 1990; 323(5):290-294.
	BN	Ho, VC and Conklin, RJ. Effect of Topical Cyclosporine Rinse on Oral Lichen Planus. <i>New Engl J Med</i> 1991; 325(6):435.
	BO	Eisen, D, Griffiths, CEM et al. Cyclosporin Wash for Oral Lichen Planus. <i>Lancet</i> 1990; 335:535-536.
	BP	Eisen, D, Ellis, CN, Voorhees, JJ. Topical cyclosporine for oral bullous disorders. <i>J Amer Acad Dermatol</i> 1990; 23(5):936-937.
	BQ	Eisen, D, Ellis, CN. Topical Cyclosporine for Oral Mucosal Disorders. <i>J Amer Acad Dermatol</i> 1990; 23(6):1259-1264.
	BR	Volc-Platzer, B, Hönigsmann, H et al. Photochemotherapy Improves Chronic Cutaneous Graft-Versus-Host Disease.
	BS	Farthing, PM, Maragou, P et al. Characteristics Of The Oral Lesions In Patients With Cutaneous Recurrent Erythema Multiforme. <i>J Oral Path Med</i> 1995; 24:9-13.
<i>WB</i>	BT	Plauth, M, Jenss, H, Meyle, J. Oral Manifestations of Crohn's Disease: An Analysis of 79 Cases. <i>J Clin Gastroenterol</i> 1991; 13(1):29-71.

EXAMINER:

*Myra B. K.*  
Not Yet AssignedDATE CONSIDERED: *6/3/01*

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609;  
Draw line through citation if not in conformance and not considered. Include a copy of this form with next  
communication to applicant